Quell Therapeutics is advancing its engineered regulatory T cell platform, with this weekly summary highlighting recent clinical and strategic progress. The company continued to emphasize the CHILL Phase 1/2 basket trial of lead candidate QEL-005 in refractory rheumatoid arthritis and systemic sclerosis as its primary value driver.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
During the week, Quell announced the addition of two new U.K. trial sites at University Hospitals Birmingham NHS Foundation Trust and Royal Free London NHS Foundation Trust, bringing the country’s total to six active centers. Sites in Germany and Spain are also ramping up following April approval of the European Clinical Trial Application, with active patient recruitment now underway.
QEL-005 is positioned as a differentiated CAR-Treg therapy designed to restore immune balance rather than rely solely on B-cell depletion, the mechanism used by many current biologics in autoimmune disease. The multinational, multi-indication study is intended to generate early safety and efficacy data while broadening the program’s clinical footprint across Europe.
Quell also hosted representatives from the Academy of Medical Sciences to discuss the outlook for the U.K. life sciences ecosystem and the role of advanced cell therapies. The company highlighted strengths such as innovative science, collaborative networks, a supportive regulatory framework and strong academic–industry links as key enablers of its CHILL program.
In parallel, Quell raised its profile with investors by showcasing its CAR-Treg platform and QEL-005 at the BioEquity Europe conference in Prague, signaling ongoing business development and networking efforts. This engagement, combined with expanding clinical operations, may support future funding, partnership opportunities and regulatory visibility.
Collectively, the week underscored steady execution for Quell Therapeutics as it scales the CHILL trial geographically and deepens its integration within the U.K. and European cell therapy ecosystem. While the program remains in early stages and still faces typical development risks, recent moves strengthen the company’s positioning in autoimmune cell therapy and set up multiple future clinical inflection points.